Apart from the above, the data in these studies [14–17, 21, 24–36] have only highlighted the value of tumor or non-tumor-related biomarkers or models as single or independent factors for OS, PFS, therapeutic approaches and clinical responses in NSCLC patients, but have ignored the improvement in prognosis and prediction when combined with PD-L1 expression. The gene discussed is CD274; the disease is neoplasm.